[C1] Corporate Exhibitions | 第4回 UTOPIAシンポジウム

セッション詳細

企業展示

[C1]Corporate Exhibitions

2026年7月7日(火) 14:10 〜 15:10

Corporate Exhibits(伊藤国際学術研究センターB2)

[C1-01]Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms

*Taro Saito¹, Arnaud Couzinet², Toshihiro Suzuki², Kei Miyakawa³, Tetsuya Nakatsura² (1. Canon Medical Diagnostics Corporation (Japan), 2. Division of Cancer Immunotherapy, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center (Japan), 3. Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security (Japan))

コメント()

[C1-02]LeukoComplete^TM アッセイの異なるラボ間における分析性能と再現性評価

Taro Saito¹, Oliver McKenzie², Daniel J. Wilson², Jalil Hakimi², *Takaya Sato¹ (1. Canon Medical Diagnostics Corporation (Japan), 2. Pegasus Biotech Inc. (Canada))

コメント()

[C1-03]バイオプロセスサポート製品・技術の展示

*Natsumi Kimura¹ (1. Merck Ltd. Process Solutions (Japan))

コメント()

[C1-04]弊社細胞培養関連製品群及び受託事業のご紹介

*Hiroyuki Hata¹ (1. Kyokuto pharmaceutical industrial Co., Ltd. (Japan))

コメント()

[C1-05]EPSグループによる医薬品・医療機器・再生医療等製品等の開発支援について

*Yasushi Ashikawa², Yuta Okugi³, Saburo Niki¹ (1. Sales Department, Sales Planning Promotion Center, EPS Corporation (Japan), 2. Government Affairs Business Planning Office, Comprehensive Planning Center, EPS Corporation (Japan), 3. Business Planning Promotion Office, Business Planning Promotion Center, Real World Evidence Business Division, EPS Corporation (Japan))

コメント()